Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 8, 2026 · Investor press release · Financial statements
Neurogene Inc.
42
Investor press release
Jun 8, 2026
| Form type | Current report (Form 8-K) |
| Event summary | Investor press release · Financial statements |
| Primary topic | Investor press release |
| About this form | Public companies file this within four business days when something important happens that investors should know about, before the next quarterly report. |
| Why this was filed | Neurogene Inc. filed this to release information to investors under Regulation FD, usually a press release, conference presentation, or other event the company considers important. Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome Exceeded target by dosing a total of 25 participants with NGN-401 in registrational trial due to strong demand from Rett syndrome community NGN-401 has been generally well-tolerated, with no cases of HLH at the 1E15 vg dose; additional interim P… |
| Labor angle | Watch for Item 2.05 (restructuring or severance), Item 5.02 (leadership changes), and Item 1.01 (major contracts that can precede workforce shifts). |
| Period of report | Jun 8, 2026 |
| Accession number | 0001404644-26-000044 |
| Reported items | Regulation FD disclosure (investor press release or presentation), Financial statements and exhibits See Analysis tab for workforce implications |
